Ziopharm Oncology Inc. (NASDAQ:ZIOP) saw unusually-high trading volume on Friday . Approximately 7,719,234 shares traded hands during mid-day trading, an increase of 189% from the previous session’s volume of 2,666,586 shares.The stock last traded at $4.92 and had previously closed at $5.67.

ZIOP has been the subject of a number of research analyst reports. Griffin Securities restated a “buy” rating and issued a $21.00 target price on shares of Ziopharm Oncology in a research note on Friday, July 1st. Vetr cut Ziopharm Oncology from a “strong-buy” rating to a “buy” rating and set a $9.76 target price for the company. in a research note on Monday, April 18th. Zacks Investment Research raised Ziopharm Oncology from a “sell” rating to a “hold” rating in a research report on Wednesday, May 11th. Raymond James Financial Inc. started coverage on Ziopharm Oncology in a research report on Thursday, June 2nd. They set a “market perform” rating for the company. Finally, Mizuho raised their price objective on Ziopharm Oncology from $6.00 to $7.00 and gave the company a “neutral” rating in a research report on Wednesday, May 11th. One research analyst has rated the stock with a sell rating, four have assigned a hold rating, one has given a buy rating and one has issued a strong buy rating to the company’s stock. The stock has a consensus rating of “Hold” and a consensus target price of $11.07.

The firm’s market capitalization is $652.38 million. The company has a 50 day moving average price of $6.28 and a 200-day moving average price of $6.98.

Ziopharm Oncology (NASDAQ:ZIOP) last released its earnings results on Tuesday, May 10th. The biotechnology company reported ($0.09) EPS for the quarter, missing analysts’ consensus estimates of ($0.08) by $0.01. The firm earned $1.97 million during the quarter, compared to analysts’ expectations of $1.89 million. The business’s revenue was up 623.9% on a year-over-year basis. During the same quarter last year, the company posted ($0.69) earnings per share. On average, equities research analysts expect that Ziopharm Oncology Inc. will post ($0.42) earnings per share for the current year.

Other hedge funds and institutional investors have added to or reduced their stakes in the company. Wells Fargo & Company MN boosted its position in Ziopharm Oncology by 18.4% in the fourth quarter. Wells Fargo & Company MN now owns 168,616 shares of the biotechnology company’s stock worth $1,402,000 after buying an additional 26,233 shares in the last quarter. Morgan Stanley boosted its position in Ziopharm Oncology by 5.1% in the fourth quarter. Morgan Stanley now owns 1,618,205 shares of the biotechnology company’s stock worth $13,447,000 after buying an additional 78,583 shares in the last quarter. California Public Employees Retirement System boosted its position in Ziopharm Oncology by 567.2% in the fourth quarter. California Public Employees Retirement System now owns 307,366 shares of the biotechnology company’s stock worth $2,554,000 after buying an additional 261,300 shares in the last quarter. Swiss National Bank boosted its position in Ziopharm Oncology by 2.2% in the fourth quarter. Swiss National Bank now owns 159,220 shares of the biotechnology company’s stock worth $1,323,000 after buying an additional 3,500 shares in the last quarter. Finally, California State Teachers Retirement System boosted its position in Ziopharm Oncology by 1.6% in the fourth quarter. California State Teachers Retirement System now owns 212,521 shares of the biotechnology company’s stock worth $1,766,000 after buying an additional 3,354 shares in the last quarter.

ZIOPHARM Oncology, Inc is a biopharmaceutical company. The Company is seeking to acquire, develop and commercialize, on its own or with partners, a portfolio of cancer therapies through synthetic immuno-oncology. Its clinical-stage product candidate, Ad-RTS-IL-12, is used with the oral activator veledimex.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.